정부/공공기관
임상시험센터
CRO
분석CRO/센트럴랩
유관기관/협회
정보서비스
해외 유관 기관
* CRO 게재 기준: CRO자율등록 기관
ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2550건이 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 401 | Active, not recruiting | Study of the Safety of Therapeutic Treatment With an Immunomodulatory Agent (N-803) in Adults With COVID-19 | COVID-19 | Biological: N-803 Other: Saline |
Phase 1 | ImmunityBio, Inc. | INDUSTRY | 1 | All | 18 Years | St. Francis, Lynwood, California, United States |
| 400 | Active, not recruiting | Study of the Safety of Therapeutic Tx With Immunomodulatory MSC in Adults With COVID-19 Infection Requiring Mechanical Ventilation | COVID | Biological: BM-Allo.MSC Biological: Placebo |
Phase 1 | ImmunityBio, Inc. | INDUSTRY | 45 | All | 18 Years ~ 80 Years | St. Francis Medical Center, Lynwood, California, United States |
| 399 | Active, not recruiting | Study of the Safety, Reactogenicity and Immunogenicity of "EpiVacCorona" Vaccine for the Prevention of COVID-19 | Covid19 | Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) Other: Placebo (sodium chloride bufus, solvent for the preparation of dosage forms for injection 0.9%) |
Phase 2 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | OTHER_GOV | 100 | All | 18 Years ~ 60 Years | Federal State Budgetary Institution of Healthcare "Medical and Sanitary Unit No. 163 of the Federal Medical and Biological Agency" (FGBUZ MSCH-163, FMBA of Russia), Koltsovo, Novosibirsk Region, Russian Federation |
| 398 | Recruiting | Study of the Sars-Cov2 Neuroinvasiveness - COVID19 | COVID19 | Drug: Cerebrospinal fluid sampling, meningeal and brain parenchyma biopsies | Not Applicable | Fondation Ophtalmologique Adolphe de Rothschild | NETWORK | 500 | All | 18 Years | Fondation A de Rothschild, Paris, France |
| 397 | Active, not recruiting | Study of the Tolerability, Safety, Immunogenicity and Preventive Efficacy of the EpiVacCorona Vaccine for the Prevention of COVID-19 | COVID-19 | Biological: EpiVacCorona (EpiVacCorona vaccine based on peptide antigens for the prevention of COVID-19) Other: Placebo (sodium chloride, a 0.9% solution for the preparation of dosage forms for injections) |
Phase 3 | Federal Budgetary Research Institution State Research Center of Virology and Biotechnology "Vector" | OTHER_GOV | 3000 | All | 18 Years | State Budgetary Healthcare Institution of the Moscow region - Krasnogorsk City Hospital # 1 (short name: SBHI MR KCH # 1), Krasnogorsk, Moscow Region, Russian Federation Federal State Autonomous Educational Institution of Higher Education - Immanuel Kant Baltic University (short name: FSAEIHE- I. Kant Baltic Federal University), Kaliningrad, Russian Federation State Autonomous Healthcare Institution - Clinical City Hospital # 7 of Kazan (short name: SAHI CCH # 7), Kazan, Russian Federation Federal State Budgetary Institution - N.I. Pirogov National Medical and Surgical Center, Ministry of Health of the Russian Federation (short name: FSBI - N.I. Pirogov NMSC, Ministry of Health of the Russian Federation), Moscow, Russian Federation Federal State Budgetary Research Institution - Academician B.V. Petrovsky Russian Research Center for Surgery (short name: FSBRI - Academician B.V. Petrovsky RRCS), Moscow, Russian Federation Research Center: Federal State Budgetary Institution - Central Clinical Hospital with Polyclinic, Administrative Office of the President of the Russian Federation (short name: FSBI Central Clinical Hospital with Polyclinic), Moscow, Russian Federation State Budgetary Healthcare Institution of the Moscow region - M.F. Vladimirsky Moscow Regional Research Clinical Institute (short name: M.F. Vladimirsky SBHI MRRCI), Moscow, Russian Federation State Budgetary Educational Institution of Higher Professional Education - Tyumen State Medical University, Ministry of Health of the Russian Federation (short name: SBEIHPE - Tyumen State Medical University, Ministry of Health of Russian Federation), Tyumen, Russian Federation |
| 396 | Completed | Study of the Use of Favipiravir in Hospitalized Subjects With COVID-19 | COVID-19 | Drug: Favipiravir + Standard of Care Drug: Standard of Care |
Phase 2 | Fujifilm Pharmaceuticals U.S.A., Inc. | INDUSTRY | 50 | All | 18 Years ~ 80 Years | HonorHealth, Scottsdale, Arizona, United States University of Miami Miller School of Medicine, Miami, Florida, United States Boston Medical Center, Boston, Massachusetts, United States Brigham and Women's Hospital, Boston, Massachusetts, United States Massachusetts General Hospital, Boston, Massachusetts, United States UMass Memorial Health Care, Worcester, Massachusetts, United States Atlantic Health System / Morristown Medical Center, Morristown, New Jersey, United States Houston Methodist Hospital, Houston, Texas, United States |
| 395 | Completed | Study of the Use of Nasal IFN-γ in Patients for the Prevention of Acute Respiratory Viral Infections, Icluding COVID-19 | Acute Respiratory Disease | Drug: Interferon gamma human recombinant (IFN-G) | Not Applicable | SPP Pharmaclon Ltd. | INDUSTRY | 630 | All | 18 Years | City Clinical Hospital named after M.E. Zhadkevich Moscow City Health Department, Moscow, Russian Federation |
